ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACAD ACADIA Pharmaceuticals

Trading 01-28 15:45:01 EST

25.73

-0.47

-1.81%

High27.21	Low25.66	Vol915.11K
Open26.36	D1 Closing26.20	Amplitude5.90%
Mkt Cap4.35B	Tradable Cap2.98B	Total Shares169.18M
T/O23.82M	T/O Rate0.79%	Tradable Shares115.85M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACAD","market":"US","secType":"STK","nameCN":"ACADIA Pharmaceuticals","latestPrice":25.725,"timestamp":1769633099889,"preClose":26.2,"halted":0,"volume":915114,"delay":0,"changeRate":-0.01812977099236633,"floatShares":115846212,"shares":169181817,"eps":1.541283,"marketStatus":"Trading","change":-0.475,"latestTime":"01-28 15:45:01 EST","open":26.36,"high":27.205,"low":25.66,"amount":23816692.90602,"amplitude":0.058969,"askPrice":25.73,"askSize":1490,"bidPrice":25.72,"bidSize":266,"shortable":3,"etf":0,"ttmEps":1.541283,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769634000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":26.2,"preHourTrading":{"tag":"盘前","latestPrice":26.34,"preClose":26.2,"latestTime":"09:28 EST","volume":613,"amount":16079.050686999999,"timestamp":1769610482017,"change":0.14,"changeRate":0.005344,"amplitude":0.014122},"postHourTrading":{"tag":"盘后","latestPrice":26.26,"preClose":26.2,"latestTime":"19:39 EST","volume":37356,"amount":978820.734,"timestamp":1769560748498,"change":0.06,"changeRate":0.00229,"amplitude":0.003435},"volumeRatio":0.718153,"impliedVol":0.3516,"impliedVolPercentile":0.3665},"requestUrl":"/m/hq/s/ACAD","defaultTab":"news","newsList":[{"id":"2604119512","title":"RBC Raises Price Target on ACADIA Pharmaceuticals to $35 From $33, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2604119512","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604119512?lang=en_us&edition=fundamental","pubTime":"2026-01-20 22:05","pubTimestamp":1768917938,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $30.84, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"gpt_icon":0},{"id":"2603868651","title":"Neuren Shares Rise on Higher Daybue Sales Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2603868651","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603868651?lang=en_us&edition=fundamental","pubTime":"2026-01-14 08:23","pubTimestamp":1768350180,"startTime":"0","endTime":"0","summary":"SYDNEY--Neuren Pharmaceuticals shares gained after its U.S. partner signaled global net sales of the Daybue treatment for Rett Syndrome could reach US$700 million in 2028.Shares were recently up 8.3% at A$20.90 on Wednesday.Neuren, a constituent of Australia's benchmark S&P/ASX 200 index, said more than 2,000 patients with Rett Syndrome have been treated with Daybue since its U.S. launch in 2023. That represents around a third of people in the U.S. with the disease.Net sales of Daybue totaled US$101.1 million in the third quarter of last year.In a recent presentation, Neuren's partner Acadia Pharmaceuticals said it has launched a new powder formulation known as Daybue Stix in the U.S. on a limited basis. That would come ahead of a full rollout by the beginning of April.Acadia has projected this would help to drive sales growth toward the US$700 million target as Daybue Stix \"could potentially enable patient growth from families who had declined to try or discontinued the liquid formula","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065169927.USD","BK7508","LU2065170008.USD","LU2065171311.SGD","NEU.AU","BK7096","LU2065171402.SGD","ACAD"],"gpt_icon":0},{"id":"2603658565","title":"ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2603658565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603658565?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:17","pubTimestamp":1768339050,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals ( ($ACAD) ) has issued an announcement. In a recent regulatory filing, ACADIA Pharmaceuticals specified that certain informa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acadia-pharmaceuticals-clarifies-form-8-k-disclosure-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acadia-pharmaceuticals-clarifies-form-8-k-disclosure-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACAD","LU2065170008.USD","LU2065171402.SGD","LU2065171311.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"2603302466","title":"ACADIA Pharmaceuticals Inc - Anticipates 2025 Net Sales to Exceed $1 Bln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603302466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603302466?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:00","pubTimestamp":1768338031,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE16Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","BK4139","LU2065169927.USD","ACAD"],"gpt_icon":0},{"id":"2603874126","title":"Acadia Pharmaceuticals projects $1.7 billion in net sales by 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2603874126","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603874126?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:01","pubTimestamp":1768312911,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals projects $1.7 billion in net sales by 2028               ACADIA Pharmaceuticals Inc. projects strong commercial growth, forecasting approximately $1.7 billion in global net...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL1Sz5sb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065170008.USD","ACAD","LU2065169927.USD","BK4139","LU2065171311.SGD"],"gpt_icon":0},{"id":"2603687946","title":"ACADIA Pharmaceuticals Provides Business and Pipeline Updates at 44TH Annual J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603687946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603687946?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:00","pubTimestamp":1768312810,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8BFXYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2065171402.SGD","ACAD","LU2065169927.USD","LU2065171311.SGD","LU2065170008.USD"],"gpt_icon":0},{"id":"2603085579","title":"Analysts Conflicted on These Healthcare Names: Cormedix (CRMD), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603085579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603085579?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:20","pubTimestamp":1768274412,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cormedix (CRMD – Research Report), BioMarin Pharma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cormedix-crmd-biomarin-pharmaceutical-bmrn-and-acadia-pharmaceuticals-acad-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cormedix-crmd-biomarin-pharmaceutical-bmrn-and-acadia-pharmaceuticals-acad-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4581","LU2065171402.SGD","BMRN","LU0029874061.USD","IE0002270589.USD","LU0128526141.USD","ACAD","BK4585","BK4566","LU2065171311.SGD","CRMD","LU2065169927.USD","IE00B19Z3B42.SGD","LU2065170008.USD","BK4588","IE00B7SZLL34.SGD","LABU","BK4139","BK4007","XLV","IE00B19Z3581.USD","HCSG","BK4137"],"gpt_icon":0},{"id":"2601365095","title":"RBC Lifts Price Target on ACADIA Pharmaceuticals to $33 From $32, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2601365095","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601365095?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:47","pubTimestamp":1767872832,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $30.53, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"gpt_icon":0},{"id":"2601814694","title":"ACADIA Pharmaceuticals Is Maintained at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2601814694","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601814694?lang=en_us&edition=fundamental","pubTime":"2026-01-07 01:31","pubTimestamp":1767720660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACAD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 12:31 ET (17:31 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD"],"gpt_icon":0},{"id":"2601815315","title":"UBS Adjusts Price Target on ACADIA Pharmaceuticals to $40 From $35, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2601815315","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601815315?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:43","pubTimestamp":1767710595,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $30.32, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"gpt_icon":0},{"id":"2601086401","title":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2601086401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601086401?lang=en_us&edition=fundamental","pubTime":"2026-01-06 15:53","pubTimestamp":1767686032,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR InfrastructureJan 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL8N3Y7095:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALHC","NLY","AAL","BLTE","AMT","BBBY","ALB","ARCT","AEO","AXSM","AJG","IE00B5TLWC47.USD","LU2125154935.USD","LU0971096721.USD","SG9999014005.SGD","BALL","BKD","AIG","WMS","BOW","BK","ALGT","LU0757428866.USD","BA","LU2249611893.SGD","BBIO","BMY","BK4178","BC","AGIO","ALL","ARVN","BP","EAT","AGNC","ALK","SGXZ23171101.USD","BK4532","APGE","BRLT","ALNY","DRUG","ADAM","BIIB","AVY","BK4135","BBWI","BAC","ACAD","BKNG"],"gpt_icon":1},{"id":"1109933314","title":"FDA Expands Indication for Blood Disorder Drug, ACADIA Pharmaceuticals' Stock Soars","url":"https://stock-news.laohu8.com/highlight/detail?id=1109933314","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109933314?lang=en_us&edition=fundamental","pubTime":"2025-12-24 21:50","pubTimestamp":1766584219,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration (FDA) has approved an expanded indication for ACADIA Pharmaceuticals' blood disorder treatment drug, sending the company's stock surging nearly 12% in pre-market...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","ACAD","LU2065171402.SGD","LU2065170008.USD","01477","BK1191","BK4139","LU2065169927.USD","BK1574"],"gpt_icon":0},{"id":"2593477851","title":"Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 12-Month Share Price Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593477851?lang=en_us&edition=fundamental","pubTime":"2025-12-21 06:27","pubTimestamp":1766269645,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has quietly put together an impressive run, with the stock up about 18% over the past month and roughly 61% over the past year, catching more investors’ attention.\nSee our latest analysis for ACADIA Pharmaceuticals.\nThat strong 12 month total shareholder return of 61 percent, alongside a roughly 45 percent year to date share price return, suggests momentum is clearly building as investors reassess ACADIA Pharmaceuticals growth prospects and risk profile at around...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/assessing-acadia-pharmaceuticals-acad-valuation-after-its-st-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/assessing-acadia-pharmaceuticals-acad-valuation-after-its-st-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065169927.USD","ACAD","BK4139","LU2065171402.SGD","LU2065170008.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2592927648","title":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2592927648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592927648?lang=en_us&edition=fundamental","pubTime":"2025-12-18 14:42","pubTimestamp":1766040152,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, LennarDec 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autozone, Courser","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD","DD","IE00B7SZLL34.SGD","BK4090","AMAT","BK4147","APD","LU0345769631.USD","DOW","ASH","CRL","BRO","AAL","ACM","BBNX","BK4548","DAL","ALB","AZO","CBT","CE","BIIB","LU1989763690.USD","CL","CPT","DG","HOUS","AVTX","BSX","CLYM","CF","SGXZ57979304.SGD","ALL","COUR","CGNX","BCAX","ACHC","SG9999001176.USD","ARDT","BK4107","AMRZ","AJG","ALSN","CMI","AXTA","BAC","CTVA","CLW","LU0234570918.USD","BTSG"],"gpt_icon":0},{"id":"2591628920","title":"ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591628920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591628920?lang=en_us&edition=fundamental","pubTime":"2025-12-16 00:10","pubTimestamp":1765815000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACAD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 11:10 ET (16:10 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACAD"],"gpt_icon":0},{"id":"2591466698","title":"BUZZ-Australia's Neuren soars as partner Acadia wins FDA nod for Rett syndrome treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2591466698","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591466698?lang=en_us&edition=fundamental","pubTime":"2025-12-15 08:42","pubTimestamp":1765759356,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren soars as partner Acadia wins FDA nod for Rett syndrome treatment** Shares of Neuren Pharmaceuticals NEU.AX soar as much as 3.8% to A$19.73, post their biggest intraday pct gain since Dec 5** Co says partner Acadia Pharmaceuticals ACAD.O received U.S. FDA approval for DAYBUE STIX  for oral solution** DAYBUE STIX is a powder formulation for treatment of Rett syndrome, a rare genetic disorder that affects brain development** Co receives royalties on net sales** YTD, shares up 57.6%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL01E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK7096","ACAD","BK7508","BK4139","LU2065171402.SGD","NEU.AU","LU2065170008.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2590501509","title":"FDA Approves Acadia Pharmaceuticals' DAYBUE STIX for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501509","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501509?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:00","pubTimestamp":1765544426,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration  has approved DAYBUE STIX  for oral solution, a new dye- and preservative-free powder formulation for the treatment of Rett syndrome in patients aged two years and older. The approval was based on bioequivalence studies showing comparable efficacy and safety to the original DAYBUE oral solution. DAYBUE STIX will be available on a limited basis in the first quarter of 2026 and more broadly in the second quarter of 2026. The original oral solution will remain available.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on December 12, 2025, and is sole","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL1BhPSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065171311.SGD","BK4139","LU2065169927.USD","LU2065170008.USD","ACAD"],"gpt_icon":0},{"id":"2590450967","title":"ACADIA Pharmaceuticals Inc - Daybue Stix Will Be Available on a Limited Basis Starting in Q1 2026 and More Broadly Early in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590450967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590450967?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:00","pubTimestamp":1765544401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6R4XJQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2065169927.USD","LU2065170008.USD","LU2065171402.SGD","ACAD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2590095445","title":"ACADIA Pharmaceuticals Announces FDA Approval of Daybue® Stix (Trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590095445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590095445?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:00","pubTimestamp":1765544401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6R4XJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171402.SGD","ACAD","LU2065170008.USD","LU2065169927.USD","BK4139","LU2065171311.SGD"],"gpt_icon":0},{"id":"2590516720","title":"ACADIA Pharmaceuticals Is Maintained at Hold by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516720","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516720?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:25","pubTimestamp":1765459500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACAD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 08:25 ET (13:25 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","SF","LU2065171402.SGD","ACAD","LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acadia.com","stockEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0514},{"period":"3month","weight":0.1629},{"period":"6month","weight":0.0995},{"period":"1year","weight":0.434},{"period":"ytd","weight":-0.0191}],"compareEarnings":[{"period":"1week","weight":0.0264},{"period":"1month","weight":0.0075},{"period":"3month","weight":0.0118},{"period":"6month","weight":0.1003},{"period":"1year","weight":0.1604},{"period":"ytd","weight":0.0199}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.059923},{"month":2,"riseRate":0.666667,"avgChangeRate":0.025516},{"month":3,"riseRate":0.428571,"avgChangeRate":0.056582},{"month":4,"riseRate":0.428571,"avgChangeRate":0.000567},{"month":5,"riseRate":0.571429,"avgChangeRate":0.061282},{"month":6,"riseRate":0.5,"avgChangeRate":-0.015184},{"month":7,"riseRate":0.590909,"avgChangeRate":0.052638},{"month":8,"riseRate":0.545455,"avgChangeRate":0.014715},{"month":9,"riseRate":0.5,"avgChangeRate":0.023984},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.024848},{"month":11,"riseRate":0.454545,"avgChangeRate":0.031974},{"month":12,"riseRate":0.545455,"avgChangeRate":0.059204}],"exchange":"NASDAQ","name":"ACADIA Pharmaceuticals","nameEN":"ACADIA Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACADIA Pharmaceuticals,ACAD,ACADIA Pharmaceuticals股票,ACADIA Pharmaceuticals股票老虎,ACADIA Pharmaceuticals股票老虎国际,ACADIA Pharmaceuticals行情,ACADIA Pharmaceuticals股票行情,ACADIA Pharmaceuticals股价,ACADIA Pharmaceuticals股市,ACADIA Pharmaceuticals股票价格,ACADIA Pharmaceuticals股票交易,ACADIA Pharmaceuticals股票购买,ACADIA Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction